CC Transcript on Seeking Alpha and IBD Leaderboard
If you are interested in reading more on ALKS, the transcript of the Jan 31 cc is available for free at seekingalphadotcom. Interesting reading, several analysts from name brand firms following this compnay closely given the detail of their questions.
Also, ALKS is an IBD leaderboard stock--which is a very short list of stocks. Current IBD notes in leaderboard are as follows:
UPDATED 11:20 AM ET | Alkermes is trying to rebound after sinking near its 20.79 buy point. After rising more than 12% from it, do not let a solid gain turn negative. Wait for shares to firm up some more before taking advantage of the retracement. At the same time, be ready to sell to avoid a loss. Backstory: The drugmaker made a transforming deal in 2011, when it acquired the drug-formulation and manufacturing business of Elan. The $1 billion acquisition gave Alkermes some lucrative products, including treatments for multiple sclerosis and schizophrenia. The company used the deal to move its headquarters to Ireland, where it benefits from lower taxes. In January, Alkermes announced positive results in an early trial of a new antipsychotic drug it is calling ALKS 3831. On Jan. 31, the company announced December-ended fiscal third-quarter results. It swung to a profit of 34 cents a share, 11 cents above views, as revenue grew 8% to $135.9 million, also above forecasts. Alkermes hiked its full-year EPS guidance to 99 cents to $1.13, above estimates. It sees full-year sales of $520 million to $545 million; the midpoint of that range is above the Street's consensus estimate. But on Feb. 1, the company priced 7.75 million shares at $22.13 each (a 4% discount to the prior day's close). The shares are being sold by a unit of Irish drugmaker Elan. Also Feb. 1, Bank of America/Merrill Lynch downgraded Alkermes to neutral from buy.